The CFO's open-market buy alongside two directors, coming right after a dilutive $200M offering, is a strong vote of confidence in the pipeline. Monitor upcoming ABCL635 Phase 2/3 data readouts and any further insider accumulation. The cluster buys suggest the recent offering-driven selloff may be overdone.
Drug in focus
ABCL drug pipeline →ABCL635
● Neutral Named in this insider cluster- Impact
- Phase
- Phase 2
- Time to market
- Phase 3 is planned to begin in 2027. Assuming a multi-year Phase 3 program followed by FDA review, potential approval would likely be 2029-2030 at the earliest, barring accelerated development.
- Next catalyst
- None dated
What to watchThe next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 18 $11.12entry
- T+1 · 3mo ago +8.00%α +7.79% · $12.01
- T+5 · 3mo ago +12.41%α +12.61% · $12.50
- T+20 · 2mo ago +4.95%α +6.69% · $11.67
- T+60 · 6d ago +7.46%α +8.46% · $11.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three AbCellera insiders, including the CFO and two directors, purchased a total of ~$975K in open-market shares over a 7-day window following a $200M dilutive offering and positive Phase 2 data for ABCL635. The cluster buys, particularly the CFO's $384K purchase, signal insider confidence in the pipeline despite the recent capital raise dilution. At ~0.03% of market cap, the dollar amount is modest but the C-suite participation and proximity to a catalyst make this a notable bullish signal.
Key Financial Metrics
Key Facts
- CFO Andrew Booth bought $384K in open-market shares on 2026-08-14 at $10.32
- Director Michael R. Hayden bought $481K on 2026-08-12 at $10.37
- Director John S. Montalbano bought $110K on 2026-08-18 at $11.03
- Total insider purchases of ~$975K represent ~0.03% of $3.3B market cap
- Buys occurred within 7 days of a $200M dilutive offering and positive Phase 2 data for ABCL635
Financial Impact
~$975K in insider open-market purchases, ~0.03% of market cap
Risk Factors
- $200M dilutive offering will significantly increase share count and dilute existing holders
- Insider purchases are small relative to market cap (~0.03%) and may not move the stock
- Biotech pipeline risk, ABCL635 Phase 2 data is early and may not replicate in larger trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ABCL-1787079683283 |
Track record
16 reports on ABCL
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +127.09% at T+20 after the Jul 29, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $11.63 Now $11.12 −4.39% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
- Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $12.46 Now $11.12 −10.75% settles Feb 8
- Aug 24, 202612w ago Insider Cluster Mixed 5/10 Entry $12.50 Now $11.12 −11.04% settles Nov 18
- Aug 18, 202612w ago Insider Cluster Bullish 5/10 Viewing Entry $11.12 to $11.95 Now $11.12 −0.00% ▲ +7.46% +8.46% vs SPY
- Aug 15, 202613w ago Institutional Cluster Bearish 6/10 Entry $11.20 to $12.46 Now $11.12 +0.71% ▼ −11.25% −14.19% vs SPY
- Aug 11, 202613w ago 424B5 Bearish 7/10 Entry $10.36 to $11.13 Now $11.12 −7.39% ▼ −7.48% −12.60% vs SPY
- Aug 10, 202614w ago 8-K Bullish 7/10 Entry $9.34 to $12.18 Now $11.12 +19.06% ▲ +30.41% +32.82% vs SPY
- Jul 29, 202615w ago 8-K Bullish 6/10 Entry $5.39 to $11.37 Now $11.12 +106.31% ▲ +110.95% +106.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers